ICU MEDICAL INC/DE
Close on Oct 19, 2026
- Market cap
- $4.04B
- P/E (TTM)
- 134.4
- Dividend yield
- –
About Icu Medical
Surgical & Medical Instruments & Apparatus, SIC 3841
ICU Medical, Inc. develops, manufactures, and sells medical devices and products used in infusion therapy, vascular access, and vital care settings. The company operates through business units that include Consumables, Infusion Systems, and Vital Care. Its offerings encompass ambulatory, syringe, and large volume infusion pumps, safety software, dedicated and non-dedicated IV sets, needlefree connectors, vascular access catheters, closed system transfer devices, tracheostomy tubes, temperature management systems, hemodynamic monitoring devices, and regional anesthesia products. ICU Medical provides these solutions primarily to acute care hospitals, wholesalers, ambulatory clinics, and alternate site care facilities, including outpatient centers and long-term care providers.
The company distributes its products globally, serving customers in more than 100 countries through a direct sales team and independent distributors. ICU Medical operates manufacturing facilities in the United States, Costa Rica, Mexico, and the Czech Republic, and maintains device service centers across several countries, including Germany, Canada, Taiwan, and Australia. Its corporate headquarters are located in San Clemente, California.
Summary of the business section of Icu Medical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ICU MEDICAL INC/DE
- Founded
- 1984
- Headquarters
- San Clemente, CA
- Address
- 951 Calle Amanecer 92763-6212
- Phone
- (949) 366-2183
- Employees
- 13,000, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- DELOITTE & TOUCHE LLP, Costa Mesa, California
Stock & identifiers
- Ticker
- ICUI
- Exchange
- Nasdaq
- Shares outstanding
- 25M, Jul 31, 2026
- Public float
- $3.23B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 3-for-2, Mar 18, 2002; 3-for-2, Apr 1, 1993
- SEC CIK
- 883984
- CUSIP
- 44930G107
- ISIN
- US44930G1076
- LEI
- 5493003NRW7LS2QZRH60
- EIN
- 33-0022692
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Vivek Jain | Chairman and CEO, Director | 276,993 |
| Virginia Ruth Sanzone | VP, General Counsel | 16,020 |
| Brian Michael Bonnell | Chief Financial Officer | 56,062 |
| Daniel Woolson | VP, GM-Infusion Capital | 17,062 |
| Ben Sousa | Chief Information Officer | 3,076 |
| Christian B. Voigtlander | Chief Operating Officer | 37,377 |
| Elisha W. Finney | Director | 4,871 |
| David F. Hoffmeister | Director | 6,004 |
| David C. Greenberg | Director | 9,714 |
| Donald Abbey | Director | 6,004 |
| Laurie Hernandez | Director | 4,862 |
| Kolleen T. Kennedy | Director | 4,539 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Vivek Jain | $6.45M | $9.20M | $3.20M | $67 | $68 |
| FY2024 Vivek Jain | $6.45M | $23.09M | $3.25M | $83 | $96 |
| FY2023 Vivek Jain | $6.81M | -$8.07M | $3.37M | $53 | $106 |
| FY2022 Vivek Jain | $5.66M | -$11.28M | $2.79M | $84 | $100 |
| FY2021 Vivek Jain | $5.07M | $13.34M | $2.65M | $127 | $152 |
| FY2020 Vivek Jain | $3.31M | $14.34M | $1.56M | $115 | $127 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“At December 31, 2025, we had approximately 13,000 employees located in over 35 countries.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 7, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 2, 2018 | Late filing | Notification of late filing |
| May 11, 2017 | Late filing | Notification of late filing |
| Feb 9, 2017 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 5, 2015 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 6, 2015 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 15, 2012 | Late filing | Notification of late filing |
| Feb 18, 2010 | Listing | Registration of securities on an exchange (Form 8-A) |
| Sep 4, 2009 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 19, 2008 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 31, 2005 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 5, 2005 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |